Jing Wu, M.D., Ph.D.


Neuro-Oncology Branch


Building 82, Room 221
Bethesda, MD 20892



Research Topics

My research focuses on 1) designing and implementing clinical trials in discovering novel therapies for glioma patients; 2) developing pre-clinical studies to provide rationales for clinical trials 3) develop correlative studies integral components of the clinical trials.


Dr. Wu graduated with a medical degree from the Capital Medical University, Beijing, China. She earned her Ph.D. in neuroscience from the University of Texas Medical Branch, Texas and completed a NIH post-doctoral fellowship both under the mentorship of Dr. William D. Willis. She completed an internship in Internal Medicine at Texas Tech University Medical Center, and a Neurology residency at The University of Texas Health Science Center, Houston, where she also served as the chief resident in 2008. Dr. Wu completed her clinical Neuro-Oncology fellowship training at The University of Texas MD Anderson Cancer Center, Houston, Texas. Dr. Wu joined the faculty of School of Medicine, University of North Carolina at Chapel Hill in 2010 as assistant professor of Neurosurgery, Neurology and Medical Oncology. Prior joining CCR, she served co-director of brain tumor program, Lineberger Comprehensive Cancer Center, University of North Carolina Cancer Network. Currently, she serves as a Tenure Track Investigator and the Director of Neuro-Oncology Fellowship Program at NOB, CCR.

She is certified both by the American Board of Psychiatry and Neurology (ABPN) in Neurology and United Council for Neurologic Subspecialties (UCNS) in Neuro-Oncology. Dr. Wu has published more than 38 peer reviewed articles and serves as an invited reviewer for many journals. She has received many academic and research awards including William James Miller Endowed Fellowship Award in Neuro-oncology and an NIH/NCI Paul Calabresi Clinical Oncology Scholar Award. She specializes in CNS neoplasms and neurological complications of systemic cancers. Her research focuses on developing preclinical studies in discovering novel therapies for glioma patients.

Selected Publications

  1. Ranjan S, Quezado M, Garren N, Boris L, Siegel C, Lopes Abath Neto O, Theeler BJ, Park DM, Nduom E, Zaghloul KA, Gilbert MR, Wu J. Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases. BMC Cancer. 2018;18(1):239.

  2. Su YT, Chen R, Wang H, Song H, Zhang Q, Chen LY, Lappin H, Vasconcelos G, Lita A, Maric D, Li A, Celiku O, Zhang W, Meetze K, Estok T, Larion M, Abu-Asab M, Zhuang Z, Yang C, Gilbert MR, Wu J. Novel Targeting of Transcription and Metabolism in Glioblastoma. Clin Cancer Res. 2018;24(5):1124-1137.

  3. Wu J, Frady LN, Bash RE, Cohen SM, Schorzman AN, Su YT, Irvin DM, Zamboni WC, Wang X, Frye SV, Ewend MG, Sulman EP, Gilbert MR, Earp HS, Miller CR. MerTK as a therapeutic target in glioblastoma. Neuro Oncol. 2018;20(1):92-102.

  4. Lu Y, Kwintkiewicz J, Liu Y, Tech K, Frady LN, Su YT, Bautista W, Moon SI, MacDonald J, Ewend MG, Gilbert MR, Yang C, Wu J. Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair. Cancer Res. 2017;77(7):1709-1718.

  5. Wu J, Armstrong TS, Gilbert MR. Biology and management of ependymomas. Neuro Oncol. 2016;18(7):902-13.

This page was last updated on August 29th, 2019